Advanced search
Publication Cover
Future Medicinal Chemistry Volume 2, 2010 - Issue 1
Submit an article Journal homepage
145
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Towards a More Robust Approach to Selecting and Prosecuting Promising Targets and Compounds

Graeme RobertsonSiena Biotech SpA, Strada del Petriccio e Belriguardo, 35, 53100Siena, ItalyCorrespondence[email protected]
View further author information
Pages 25-34 | Published online: 22 Dec 2009

Bibliography

  • Caricasole A , BakkerA, CopaniAet al. Two sides of the same coin: Wnt signalling in neurodegeneration and neurooncology. Biosci. Rep. 25(5–6), 309–327 (2005).
  • Sioud M . Main approaches to target discovery and validation.Methods Mol. Biol.360, 1–12 (2007).
  • Anders HJ , VielhauerV. Identifying and validating novel targets with in-vivo disease models. Drug Discov. Today12(11–12), 446–451 (2007).
  • van Es HH , ArtsGJ. Biology calls the targets: combining RNAi and disease biology.Drug Discov. Today10(20), 1385–1391 (2005).
  • Natt F . siRNAs in drug discovery: target validation and beyond.Curr. Opin. Mol. Ther.9(3), 242–247 (2007).
  • Iorns E , LordCJ, TurnerNet al. Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 6, 556–568 (2007).
  • Kourtidis A , EifertC, ConklinDS. RNAi applications in target validation.Ernst Schering Res. Found. Workshop (61), 1–21 (2007).
  • Eggert US , KigerAA, RichterCet al. Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol. 2(12), E379 (2004).
  • Edwards AM , BountraC, KerrDJet al. Open access chemical and clinical probes to support drug discovery. Nature Chem. Biol. 5(7), 436–440 (2009).
  • Jones SW , LindsayMA. Overview of target validation and the impact of oligonucleotides.Curr. Opin. Mol. Ther.6(5), 546–550 (2004).
  • Altar CA , VawterMP, GinsbergSD. Target identification for CNS diseases by transcriptional profiling.Neurophsychopharmacology34, 18–54 (2009).
  • Azorsa DO , GonzalesIM, BasuGDet al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J. Transl. Med. 7, 43 (2009).
  • Jones D . Teaming up to tackle RNAi delivery challenge.Nat. Rev. Drug Discov.8, 525–526 (2009).
  • Brasnjevic I , SteinbuschHW, SchmitzC, Martinez-MartinezP. European NanoBioPharmaceutics research initiative: delivery of peptide and protein drugs over the blood–brain barrier.Prog. Neurobiol.87(4), 212–251 (2009).
  • Denora N , TrapaniA, LaquintanaV, LopedotaA, TrapaniG. Recent advances in medicinal chemistry and pharmaceutical technology – strategies for drug delivery to the brain.Curr. Top. Med. Chem.9(2), 182–196 (2009).
  • Juillerat-Jeanneret L . The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles?Drug Discov. Today13(23–24), 1099–1106 (2008).
  • Hansel TT , BarnesPJ. New drugs for exacerbations of chronic obstructive pulmonary disease.Lancet374(9691), 744–755 (2009).
  • Rhodes CJ , DavidsonA, GibbsJS, WhartonJ, WilkinsMR. Therapeutic targets in pulmonary arterial hypertension.Pharmacol. Ther.121(1), 69–88 (2009).
  • Resende RR , UlrichH, FariaM. Is there a rational approach for increasing drug specificity? Considerations on CNS target choice and validation.Recent Pat. CNS Drug Discov.2(1), 37–46 (2007).
  • Hurko O , RyanJL. Translational research in central nervous system drug discovery.NeuroRx.2(4), 671–682 (2005).
  • Haney SA , LaPanP, PanJet al. High-content screening moves to the front of the line. Drug Discov. Today 11(19–20), 889–894 (2006).
  • Bender A , BojanicD, DaviesJWet al. Which aspects of HTS are empirically correlated with downstream success? Curr. Opin. Drug Discov. Dev. 11(3), 327–337 (2008).
  • Fecke W , GianfriddoM, GaviraghiGet al. Small molecule drug discovery for Huntington’s Disease. Drug Discov. Today 14(9–10), 453–464 (2009).
  • Varma H , LoDC, StockwellBR. High throughput screening for neurodegeneration and complex disease phenotypes.Comb. Chem. High Throughput Screen.11(3), 238–248 (2008).
  • Bickle M . High-content screening: a new primary screening tool?iDrugs11(11), 822–826 (2008).
  • Gasparri F , SolaF, BandieraTet al. High-content analysis of kinase activity in cells. Comb. Chem. High Throughput Screen. 11(7), 523–536 (2008).
  • Denner P , SchmalowskyJ, PrechtlS. High-content analysis in preclinical drug discovery.Comb. Chem. High Throughput Screen.11(3), 216–230 (2008).
  • Eglen RM , GilchristA, ReisineT. An overview of drug screening using primary and embryonic stem cells.Comb. Chem. High Throughput Screen.11(7), 566–572 (2008).
  • Weiss A , RoscicA, PaganettiP. Inducible mutant huntingtin expression in HN10 cells reproduces Huntington’s disease-like neuronal dysfunction.Mol. Neurodegener.4, 11 (2009).
  • Bakker A , CaricasoleA, GaviraghiGet al. How to achieve confidence in drug discovery and development: managing risk (from a reductionist to a holistic approach). ChemMedChem. 4(6), 923–933 (2009).
  • Dunne A , JowettM, Rees,S. Use of primary human cells in high-throughput screens.Methods Mol. Biol.565, 239–257 (2009).
  • Haney SA . RNAi and high-content screening in target identification and validation.iDrugs8(12), 997–1001 (2005).
  • Berg EL , KunkelEJ, HytopoulosEet al. Characterization of compound mechanisms and secondary activities by BioMAP analysis. J. Pharm. Toxicol. Methods 53, 67–74 (2006).
  • Butcher EC . Can cell systems biology rescue drug discovery?Nat. Rev. Drug Discov.4(6), 461–467 (2005).
  • Markou A , ChiamuleraC, GeyerMAet al. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 34(1), 74–89 (2009).
  • Wehling M . Assessing the translatability of drug projects: what needs to be scored to predict success?Nat. Rev. Drug Discov.8(7), 541–546 (2009).
  • Charnley N , DonaldsonS, PriceP. Imaging angiogenesis.Methods Mol. Biol.467, 25–51 (2009).
  • Katz JD , NayyarG, NoethE. Overview of imaging in inflammatory arthritis.Ann. NY Acad. Sci.1154, 10–17 (2009).
  • Virostko J , PowersAC. Molecular imaging of the pancreas in small animal models.Gastroenterology136(2), 407–409 (2009).
  • Kola I , HazudaD. Innovation and greater probability of success in drug discovery and development from target to biomarkers.Curr. Opin. Biotech.16(6), 644–646 (2005).
  • Kola I . The state of innovation in drug development.Clin. Pharm. Ther.83(2), 227–230 (2008).
  • Shin J , KayserSR, LangaeeTY. Pharmacogenetics: from discovery to patient care.Am. J. Health Syst. Pharm.66(7), 625–637 (2009).
  • Yip S , ShahK. Stem-cell based therapies for brain tumors.Curr. Opin. Mol. Ther.10(4), 334–342 (2008).
  • Fu J , LiuZG, LiuXM, ChenFRet al. Glioblastoma stem cells resistant to temozolomide-induced autophagy. Chin. Med. J. (Engl.) 122(11), 1255–1259 (2009).
  • Vescovi AL , GalliR, ReynoldsBA. Brain tumour stem cells.Nat. Rev. Cancer6(6), 425–436 (2006).
  • Sultana SR , RoblinD, O‘ConnellD. Translational research in the pharmaceutical industry: from theory to reality.Drug Discov. Today12(9–10), 419–425 (2007).
  • Burczynski ME . Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy.Toxicology Lett.186(1), 18–21 (2009).
  • Weiss B . Chemobrain: a translational challenge for neurotoxicology.Neurotoxicology41129(5), 891–898 (2008).
  • Gradhand U , LangT, SchaeffelerEet al. Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J. 8(1), 42–52 (2008).
  • Ali ZK , KimRJ, YslaFM. CYP2C9 polymorphisms: considerations in NSAID therapy. Curr. Opin. Drug Discov. Devel.12(1), 108–114 (2009).
  • Ferrer-Dufol A , Menao-GuillenS. Toxicogenomics and clinical toxicology: an example of the connection between basic and applied sciences.Toxicol. Lett.186(1), 2–8 (2009).
  • Collings FB , VaidyaVS. Novel technologies for the discovery and quantitation of biomarkers of toxicity.Toxicology245(3), 167–174 (2008).
  • Ma‘ayan A , JenkinsSL, GoldfarbJet al. Network analysis of FDA approved drugs and their targets. Mt Sinai J. Med. 74(1), 27–32 (2007).
  • MacArthur BD , Ma‘ayanA, LemischkaIR. Toward stem cell systems biology: from molecules to networks and landscapes.Cold Spring Harb. Symp. Quant. Biol.73, 211–215 (2008).
  • Sivachenko AY , YuryevA. Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism.Expert Opin. Ther. Targets.11(3), 411–421 (2007).
  • Rosa DD , IsmaelG, LagoLDet al. Molecular-targeted therapies: lessons from years of clinical development. Cancer Treat. Rev. 34(1), 61–80 (2008).
  • Shanks N , GreekR, GreekJ. Are animal models predictive for humans?Phil. Ethics Humanities Med.4, 2 (2009).
  • Watterson C , LanevschiA, HornerJet al. A comparative analysis of acute-phase proteins as inflammatory biomarkers in preclinical toxicology studies: implications for preclinical to clinical translation. Toxicol. Pathol. 37(1), 28–33 (2009).
  • Burgun A , BodenreiderO. Accessing and integrating data and knowledge for biomedical research.Yearb Med. Inform.91–101 (2008).
  • Renner S , van Otterlo WAL, Seoane MD. Bioactivity-guided mapping and navigation of chemical space. Nat. Chem. Biol.5(8), 585–592 (2009).
  • Richard AM , GoldLS, NicklausMC. Chemical structure indexing of toxicity data on the internet: moving toward a flat world.Curr. Opin. Drug Discov. Devel.9(3), 314–325 (2006).
  • Di L , KernsEH, CarterGT. Drug-like property concepts in pharmaceutical design.Curr. Pharm. Des.15(19), 2184–2194 (2009).
  • Vistoli G , PedrettiA, TestaB. Assessing drug-likeness – what are we missing?Drug Discov. Today13(7–8), 285–294 (2008).
  • Degtyarenko K , EnnisM, GaravelliJS. “Good annotation practice” for chemical data in biology.In Silico Biol.7(Suppl. 2), S45–S56 (2007).
  • Paolini GV , ShaplandRH, van Hoorn WP et al. Global mapping of pharmacological space. Nat. Biotechnol.24(7), 805–815 (2006).
  • Bender A , DanielW, YoungDWet al. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprints. Comb. Chem. High Throughput Screen. 10(2), 719–731 (2007).
  • Rhodes DR , Kalyana-SundaramS, TomlinsSAet al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9(5), 443–454 (2007).
  • Lamb J , CrawfordED, PeckDet al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006).
  • Cases M , MestresJ: A chemogenomic approach to drug discovery: focus on cardiovascular diseases.Drug Discov. Today14(9–10), 479–485 (2009).
  • Goldstein DM , GrayNS, ZarrinkarPP. High-throughput kinase profiling as a platform for drug discovery.Nat. Rev. Drug Discov.7(5), 391–397 (2008).
  • Wang J : Comprehensive assessment of ADMET risks in drug discovery.Curr. Pharm. Des.15(19), 2195–2219 (2009).
  • Shon J , OhkawaH, HammerJ: Scientific workflows as productivity tools for drug discovery.Curr. Opin. Drug Discov. Devel.11(3), 381–388 (2008).
  • Hopkins AL , GroomCR. The druggable genome.Nat. Rev. Drug Discov.1(9), 727–730 (2002).
  • Fuentes G , OyarzabalJ, RojasAM. Databases of protein–protein interactions and their use in drug discovery.Curr. Opin. Drug Discov. Devel.12(3), 358–366 (2009).
  • Kumar P , WuH, McBrideJLet al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149), 39–45 (2007).
  • De Souza EB , CloadST, PendergrastPSet al. Novel therapeutic modalities to address nondrugable protein interaction targets. Neuropsychopharmacology. 34(1), 142–158 (2009).
  • Schnur DM . Recent trends in library design: ‘rational design’ revisited.Curr. Opin. Drug Discov. Devel.11(3), 375–380 (2008).
  • Price DA , BlaggJ, JonesL, GreeneN, WagerT. Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opin. Drug Metab. Toxicol.5(8), 921–931 (2009).
  • Leeson PD , SpringthorpeB. The influence of drug-like concepts on decision-making in medicinal chemistry.Nat. Rev. Drug Discov.6(11), 881–890 (2007).
  • Dragunow M . High-content analysis in neuroscience.Nat. Rev. Neurosci.9(10), 779–788 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.